Search

Your search keyword '"Wendl, Michael"' showing total 551 results

Search Constraints

Start Over You searched for: Author "Wendl, Michael" Remove constraint Author: "Wendl, Michael"
551 results on '"Wendl, Michael"'

Search Results

1. Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages

2. Tumour evolution and microenvironment interactions in 2D and 3D space

4. Epigenetic regulation during cancer transitions across 11 tumour types

5. Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma

6. Author Correction: Epigenetic and transcriptomic characterization reveals progression markers and essential pathways in clear cell renal cell carcinoma

7. Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin

8. Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment

9. Pan-cancer proteogenomics connects oncogenic drivers to functional states

10. Author Correction: Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples.

11. Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples.

12. Spatially restricted drivers and transitional cell populations cooperate with the microenvironment in untreated and chemo-resistant pancreatic cancer

13. Author Correction: Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment

14. Comprehensive Characterization of Cancer Driver Genes and Mutations

15. Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics

16. Systematic Analysis of Splice-Site-Creating Mutations in Cancer

17. Pathogenic Germline Variants in 10,389 Adult Cancers.

18. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers.

20. Table S5 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma

21. Supplementary Data 1 from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma

22. Supplementary Figures from Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma

23. Spatially interacting phosphorylation sites and mutations in cancer

24. Co-evolution of tumor and immune cells during progression of multiple myeloma

25. Characteristics of de novo structural changes in the human genome

26. Comprehensive molecular profiling of lung adenocarcinoma

27. Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages

28. Combining the Tyrosine Kinase Inhibitor Cabozantinib and the mTORC1/2 Inhibitor Sapanisertib Blocks ERK Pathway Activity and Suppresses Tumor Growth in Renal Cell Carcinoma

29. Systematic Analysis of Splice-Site-Creating Mutations in Cancer

30. Driver Fusions and Their Implications in the Development and Treatment of Human Cancers

32. Whole-genome analysis informs breast cancer response to aromatase inhibition

33. Pan-cancer proteogenomics connects oncogenic drivers to functional states

34. Integrative multi-omic cancer profiling reveals DNA methylation patterns associated with therapeutic vulnerability and cell-of-origin

35. Comprehensive genomic characterization defines human glioblastoma genes and core pathways

37. Data from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma

38. Table S5 from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma

39. Supplementary Figures from Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma

40. Supplementary Table TS1 from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis

41. Supplementary Figure FS2 from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis

42. Data from Comprehensive Characterization of the Multiple Myeloma Immune Microenvironment Using Integrated scRNA-seq, CyTOF, and CITE-seq Analysis

44. Single-Cell Discovery and Multiomic Characterization of Therapeutic Targets in Multiple Myeloma

45. Histopathologic and proteogenomic heterogeneity reveals features of clear cell renal cell carcinoma aggressiveness

46. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

47. Combined burden and functional impact tests for cancer driver discovery using DriverPower

48. Integrative pathway enrichment analysis of multivariate omics data

49. Pathway and network analysis of more than 2500 whole cancer genomes

50. Divergent mutational processes distinguish hypoxic and normoxic tumours

Catalog

Books, media, physical & digital resources